

Remo Holanda de Mendonça Furtado

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9402226/publications.pdf>

Version: 2024-02-01

37
papers

4,582
citations

567144

15
h-index

395590

33
g-index

37
all docs

37
docs citations

37
times ranked

6802
citing authors

#	ARTICLE	IF	CITATIONS
1	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet, The</i> , 2019, 393, 31-39.	6.3	1,958
2	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 2022-2031.	1.6	523
3	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 2528-2536.	1.6	415
4	Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. <i>Lancet, The</i> , 2021, 397, 2253-2263.	6.3	366
5	Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. <i>New England Journal of Medicine</i> , 2021, 385, 406-415.	13.9	342
6	Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. <i>Lancet, The</i> , 2020, 396, 959-967.	6.3	278
7	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , 2019, 139, 2516-2527.	1.6	224
8	Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 586-594.	5.5	145
9	Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 181-264.	0.3	45
10	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. <i>Circulation</i> , 2020, 142, 734-747.	1.6	44
11	Stem cell therapy in ST-segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double-blind randomized trial. <i>Clinical Cardiology</i> , 2018, 41, 392-399.	0.7	32
12	Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. <i>Journal of the American College of Cardiology</i> , 2020, 75, 289-300.	1.2	29
13	Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2020, 41, 1625-1632.	1.0	27
14	Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 77, 259-267.	1.2	24
15	Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulation cOronavirus) – Coalition IV trial. <i>American Heart Journal</i> , 2021, 238, 1-11.	1.2	19
16	What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials. <i>Cardiology and Therapy</i> , 2020, 9, 59-73.	1.1	16
17	Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. <i>Circulation</i> , 2022, 145, 1581-1591.	1.6	13
18	Performance of acute coronary syndrome approaches in Brazil: a report from the BRACE (Brazilian Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Outcomes, 2020, 6, 284-292.	1.8	10

#	ARTICLE	IF	CITATIONS
19	Platelet Reactivity in Patients With Acute Coronary Syndromes Awaiting Surgical Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1277-1286.	1.2	10
20	Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011382.	1.4	10
21	Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 643-654.	2.2	10
22	Relation of High Lipoprotein (a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease. <i>Advances in Therapy</i> , 2020, 37, 4568-4584.	1.3	8
23	The Use of Oral Beta-Blockers and Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: a Long-Term Follow-Up Study. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 435-442.	1.3	7
24	Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 217-224.	1.0	6
25	Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial. <i>Advances in Therapy</i> , 2020, 37, 420-430.	1.3	6
26	Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial. <i>International Journal of Cardiology</i> , 2019, 291, 36-41.	0.8	3
27	Diabetes association with self-reported health, resource utilization, and prognosis post-myocardial infarction. <i>Clinical Cardiology</i> , 2020, 43, 1352-1361.	0.7	3
28	Is adenosine associated with sudden death in schizophrenia? A new framework linking the adenosine pathway to risk of sudden death. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 84, 29-34.	2.9	2
29	Platelet function, coagulation and fibrinolysis in patients with previous coronary and cerebrovascular ischemic events. <i>Clinics</i> , 2019, 74, e1222.	0.6	2
30	Cardiology Training in Brazil and Developed Countries: Some Ideas for Improvement. <i>Arquivos Brasileiros De Cardiologia</i> , 2019, 113, 768-774.	0.3	2
31	Influence of proven oral therapies in the very old with acute coronary syndromes: A 15-year experience. <i>International Journal of Cardiology</i> , 2015, 198, 213-215.	0.8	1
32	Associação entre Terapia com Estatinas e Menor Incidência de Hiperglicemia em Pacientes Internados com Síndromes Coronarianas Agudas. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 116, 285-294.	0.3	1
33	Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction. <i>Advances in Therapy</i> , 2022, 39, 1832-1843.	1.3	1
34	Ejection fraction versus B-type natriuretic peptide for revascularization strategy in left main disease: two sides of the same coin or a wooden nickel?. <i>European Journal of Heart Failure</i> , 2020, 22, 880-883.	2.9	0
35	Factors associated with actively working in the very long-term following acute coronary syndrome. <i>Clinics</i> , 2021, 76, e2553.	0.6	0
36	Age-adjusted D-dimer cutoffs to guide anticoagulation in COVID-19 – Authors' reply. <i>Lancet</i> , The, 2021, 398, 1304.	6.3	0

#	ARTICLE	IF	CITATIONS
37	Dapagliflozin in patients with COVID-19: mind the kidneys – Authors' reply. Lancet Diabetes and Endocrinology, 2022, 10, 98-99.	5.5	0